Log In
Print this Print this

40C7, CR8020

  Manage Alerts
Collapse Summary General Information
Company AIMM Therapeutics B.V.
DescriptionHuman mAb against influenza A virus
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationInfluenza virus
Indication DetailsTreat influenza A (H3N2) virus infection
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today